Amarin Stock Price, News & Analysis

Amarin Corporation announced substantial findings regarding VASCEPA® (icosapent ethyl) from the ACC.21 conference. The REDUCE-IT trial showed a 55% reduction in total plaque volume and a 61% reduction in non-calcified plaque volume, indicating significant cardiovascular risk reduction. Analyses confirmed that icosapent ethyl significantly cut ischemic events by 30-40% in dyslipidemic patients. This data emphasizes the efficacy of icosapent ethyl in managing cardiovascular risk, reinforcing its status as the only approved therapy for this purpose in the U.S., Canada, and Europe.

Amarin Corporation presented new analyses from the REDUCE-IT HEART FAILURE study at ACC.21, highlighting a potential correlation between on-treatment serum EPA levels and reduced incidences of new heart failure and related hospitalizations. The analyses, led by Dr. Deepak L. Bhatt, showed that achieving EPA levels above 150 µg/mL could be beneficial. Despite the overall trial not demonstrating significance for heart failure rates, these findings suggest further exploration is warranted. The study involved 8,179 patients, emphasizing the urgent need to address heart failure, projected to affect over 8 million in the U.S. by 2030.

Amarin Corporation plc (NASDAQ:AMRN) announced that research on VASCEPA® (icosapent ethyl) will be featured in seven presentations at the ACC.21, the American College of Cardiology’s 70th Annual Scientific Session from May 15-17, 2021. Key studies include insights from the REDUCE-IT HF trial and findings on the effects of icosapent ethyl on cardiovascular health. This research aims to address the significant cardiovascular disease burden and is presented by various academic collaborators, emphasizing Amarin's commitment to advancing cardiovascular treatment.

Amarin Corporation reported Q1 2021 revenue of $142.2 million, a 3% decline from Q1 2020 due to COVID-19, severe weather, and increasing generic competition for VASCEPA. Operating expenses decreased by $29 million, leading to a net loss of $1.6 million, an improvement from $20.6 million in Q1 2020. The company received European marketing authorization for VAZKEPA, with a launch planned in Germany by Q3 2021. Amarin ended Q1 with $538.7 million in cash and no debt, emphasizing plans to expand VAZKEPA’s market reach amid ongoing generic competition and COVID-related challenges.

Amarin Corporation plc (NASDAQ:AMRN) announced the retirement of Joseph T. Kennedy as Executive Vice President and General Counsel, with a search underway for his replacement. Kennedy will remain in his role until a successor is found, ensuring a smooth transition. He has served Amarin for a decade, significantly contributing to its evolution from a clinical stage to a commercial entity. The company aims to capitalize on global market opportunities and is focused on advancing cardiovascular disease management.

Amarin Corporation announced that the MHRA has granted Marketing Authorization for VAZKEPA (icosapent ethyl) in Great Britain, targeting cardiovascular risk reduction in high-risk, statin-treated adults with elevated triglycerides. This follows the EU authorization received earlier. The approval is based on substantial evidence from the REDUCE-IT study, which showed a 25% relative risk reduction in major cardiovascular events. The company emphasizes its commitment to expanding access to VAZKEPA across Europe, addressing urgent unmet needs amid rising cardiovascular disease rates.

Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on April 29, 2021, at 7:30 a.m. ET to discuss its Q1 2021 financial results and provide an operational update. The call follows the early release of the financial results on the same day. Interested parties can listen via the company's website or by calling 888-506-0062 within the U.S. A replay will be available for two weeks. Management will also take questions from participants during the call.

Amarin focuses on innovative solutions for cardiovascular disease management.

Amarin Corporation announced significant findings from the EVAPORATE trial, presented at the ESC Preventive Cardiology 2021. The trial studied the effect of VASCEPA® (icosapent ethyl) on coronary plaque in patients on statin therapy. Results showed a 17% regression in low attenuation plaque volume over 18 months. At 9 months, significant changes in plaque stability were noted, sustained through 18 months. While the study suggests VASCEPA's potential cardiovascular benefits, the small sample size of 80 patients limits the findings. Further research is needed to fully understand these effects.

Amarin Corporation plc (NASDAQ:AMRN) announces the retirement of John F. Thero as President and CEO, effective August 1, 2021. Karim Mikhail, currently Senior VP and Head of Commercial for Europe, will succeed him. Mikhail brings over 20 years of experience from Merck, where he oversaw the launch of numerous pharmaceutical products. Under Thero's leadership, Amarin achieved significant milestones, including the successful launch of VASCEPA and international expansion plans. The transition aims to position Amarin for accelerated global growth, particularly with its upcoming European launch of VAZKEPA.